Twin Tree Management LP Sells 408,412 Shares of Danaher Corporation $DHR

Key Points

• Twin Tree Management LP significantly reduced its stake in Danaher Corporation by 90.8% in Q1, now holding 41,288 shares valued at $8.46 million.
• In its most recent financial results, Danaher reported $1.80 EPS, exceeding estimates, with revenue of $5.94 billion, up 3.4% year-over-year.
• Seventeen analysts currently have a Buy rating on Danaher stock, with a consensus price target of $247.61, indicating a positive outlook on the company's performance.

Twin Tree Management LP lowered its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 90.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 41,288 shares of the conglomerate's stock after selling 408,412 shares during the quarter. Twin Tree Management LP's holdings in Danaher were worth $8,464,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently modified their holdings of DHR. Bank Pictet & Cie Europe AG increased its position in shares of Danaher by 22.8% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 192,731 shares of the conglomerate's stock valued at $44,241,000 after buying an additional 35,730 shares during the period. Gallagher Fiduciary Advisors LLC boosted its stake in Danaher by 9.7% during the fourth quarter. Gallagher Fiduciary Advisors LLC now owns 1,065 shares of the conglomerate's stock worth $244,000 after acquiring an additional 94 shares in the last quarter. Alaethes Wealth LLC boosted its stake in Danaher by 1.7% during the fourth quarter. Alaethes Wealth LLC now owns 6,757 shares of the conglomerate's stock worth $1,553,000 after acquiring an additional 115 shares in the last quarter. Accredited Wealth Management LLC bought a new stake in Danaher during the fourth quarter worth about $40,000. Finally, Aptus Capital Advisors LLC boosted its stake in Danaher by 8.6% during the fourth quarter. Aptus Capital Advisors LLC now owns 7,078 shares of the conglomerate's stock worth $1,626,000 after acquiring an additional 562 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on DHR. Barclays reissued an "overweight" rating and set a $225.00 price objective (up previously from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. UBS Group dropped their target price on shares of Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research note on Wednesday, July 23rd. Evercore ISI dropped their target price on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Wells Fargo & Company dropped their target price on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 23rd. Finally, Deutsche Bank Aktiengesellschaft dropped their target price on shares of Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Seventeen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, Danaher has a consensus rating of "Moderate Buy" and an average target price of $246.35.

Insiders Place Their Bets

In related news, Director Teri List sold 2,778 shares of the firm's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 11.20% of the company's stock.

Danaher Stock Performance

DHR stock traded down $4.39 during midday trading on Wednesday, reaching $199.40. 3,468,205 shares of the company's stock traded hands, compared to its average volume of 2,972,602. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.90. The stock has a market cap of $142.78 billion, a P/E ratio of 27.33, a PEG ratio of 2.87 and a beta of 0.75. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The stock's 50-day moving average is $201.97 and its 200 day moving average is $199.49.

Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. The business had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm's revenue was up 3.4% on a year-over-year basis. During the same period in the prior year, the company earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.